Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

World Journal of Oncology - Canada
doi 10.14740/wjon1244
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elmer Press, Inc.

Related search

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Biomedical Journal
Medicine
2015English

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients With Advanced Non-Small Cell Lung Cancer

Current Gerontology and Geriatrics Research
GerontologyGeriatrics
2010English

The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

2013English

P1.01-36 Thoracic Surgery in Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma

Oncology Letters
Cancer ResearchOncology
2020English

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Journal of Cancer
Oncology
2018English

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

JAMA - Journal of the American Medical Association
Medicine
2014English

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Clinical Studies on Conformal Radiotherapy Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Second-Line Treatment of Non-Small Cell Lung Cancer

Tropical Journal of Pharmaceutical Research
PharmacologyPharmaceutical Science
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy